China Healthcare Weekly (May.12) - Three Globalization Strategies, GLP-1/Weight Loss Drug, Bio-Heart
There're three ways for companies to enter global markets, but the results are different.Late-comers can still turn things around, such as GLP-1...
296 Views
China Healthcare Weekly (May.5)- 2nd Wave of COVID, Valuation Logic of China's Core Assets, Lifetech
It's time to talk about the 2nd wave of COVID in China.Investors need to understand deep meaning/valuation logic of China's core assets so as not...
297 Views
Zhejiang Supcon Technology GDR Listing - Momentum Has Been Strong and Not a Large Deal to Process
Zhejiang Supcon Technology (688777 CH) is looking to raise around US$347m in its Swiss GDR listing. Huatai and CLSA are bookrunners on the deal.
373 Views
China Healthcare Weekly (Apr.7)- Pacemaker VBP, FDA Changes Game Rule, Industry Beta Vs Fundamentals
China starts pacemaker VBP, which worth investors' vigilance. FDA changes game rules on accelerated approval standards. Beta disappears without...
410 Views
Fangda Carbon New Material GDR Listing - Share Price Has Outperformed Index over the past 3 Months
Fangda Carbon New Material Co, Ltd. (600516 CH) is looking to raise around US$124m in its Swiss GDR listing. Huatai is the sole bookrunner in the...
460 Views